Health Condition 1: G245- Blepharospasm Health Condition 2: G249- Dystonia, unspecified Health Condition 3: G242- Idiopathic nonfamilial dystonia Health Condition 4: G244- Idiopathic orofacial dystonia Health Condition 5: G248- Other dystonia Health Condition 6: G243- Spasmodic torticollis
Conditions
Interventions
Intervention1: Repetitive transcranial magnetic stimulation: Dose, frequency route of administration: Repetitive TMS will be given to the patients by using Magstim Rapid- 2 (Whiteland, Walsh, UK) with
Sponsors
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: As dystonia is a clinical diagnosis and there are no clinically available laboratory tests or imaging techniques, nor are there validated diagnostic criteria that can be applied, patients with a clinical diagnosis of focal dystonia in the form of benign essential blepharospasms, craniofacial dystonia, cervical dystonia, laryngeal dystonia, lingual dystonia, writer s cramp, musician dystonia, focal hand dystonia, leg dystonia will be included in the trial. Patients of the age group of more than 18 years will be included. Patients who have given a written informed consent to participate in the study will be included.
Exclusion criteria
Exclusion criteria: Patients with a history of head trauma, peripheral trauma, encephalitis, meningitis, toxin exposure, drug exposure, perinatal anoxia will be excluded. Patients with a presence of neurological abnormality like seizures, dementia, ataxia, weakness, spasticity, amyotrophy, clinical evaluation suggesting a psychogenic cause, abnormal brain imaging, abnormal laboratory findings will be excluded. Pregnant patients and lactating mothers will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Improvement in UDRS, BFMDRS, JRS, physician rating scale, patient rating scale, Modified TWSTRS, WCRS, handwriting will be recorded after 1 month, 2 months and 3 months following botulinum toxin A injection. 2. Improvement in UDRS, BFMDRS, JRS, physician rating scale, patient rating scale, Modified TWSTRS, WCRS, handwriting will be recorded after 1 month, 2 months and 3 months following rTMS sessions. 3.Comparision of the improvement, if any, following botulinum toxin A and rTMS in UDRS, BFMDRS, JRS, physician rating scale, patient rating scale, Modified TWSTRS, WCRS, handwriting will be recorded after 1 month, 2 months and 3 months. Timepoint: 1 month, 2 months and 3 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Adverse effects following rTMS and /or BoNT if any, in patients of dystonia will be assessed at 1 month, 2 month and 3 months.Timepoint: 1 month, 2 month and 3 months. | — |
Countries
India
Contacts
Public ContactRuchika Tandon
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow
Outcome results
None listed